Among mpox vaccine-eligible men in the U.S., two doses of the Jynneos vaccine reduced the risk of mpox by 9.6 times and one dose reduced the risk by 7.4 times, according to the CDC.
The researchers analyzed data from 9,544 mpox cases among men between the ages of 18 and 49 that were reported during July 31 through Oct. 1 from 43 U.S. jurisdictions. There was not a significant variation of efficacy between whether the vaccine was delivered intradermally — when a fifth of a dose is administered in between layers of skin — or subcutaneously, but to "optimize strength of protection," eligible people should receive two doses, the researchers wrote.